Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
Saved in:
| Title: | Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. |
|---|---|
| Authors: | Propper, D.1, Davidenko, I.2, Bridgewater, J.3, Kupcinskas, L.4, Fittipaldo, A.5, Hillenbach, C.6, Klughammer, B.6, Ducreux, M.7 |
| Source: | Annals of Oncology. Jul2014, Vol. 25 Issue 7, p1384-1390. 7p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdu176 |
